New immunotherapy combo aims to boost hodgkin lymphoma remission

NCT ID NCT05949931

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether adding the immunotherapy drug penpulimab to standard AVD chemotherapy improves outcomes for people with newly diagnosed advanced classic Hodgkin lymphoma. About 108 adults will receive either concurrent or sequential treatment over several cycles. The main goal is to see how many patients achieve complete remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Penpulimab (an immunotherapy drug) combined with AVD chemotherapy
What this could lead to: If successful, this could offer a more effective first-line treatment for advanced Hodgkin lymphoma, potentially improving remission rates.
What could go wrong: This is an early Phase 2 trial with only 108 participants, so results may not apply to all patients. Side effects from combining immunotherapy with chemotherapy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSIC HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLASSIC HODGKIN LYMPHOMA

Contacts and locations

Locations

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.